Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: In vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 10, 2007, Pages 1556-1562

  Curtet, Chantal ^a   Carlier, Thomas ^b   Mirallié, Eric ^b   Bodet Milin, Caroline ^b   Rousseau, Caroline ^c   Barbet, Jacques ^a   Kraeber Bodéré, Francoise ^b  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Rene Gauducheau Cancer Center   (France)

Author keywords

18F FDG; Gamma probe; Radioguided surgery; Recurrences; Thyroid cancer

Indexed keywords

BISMUTH GERMANATE; CAESIUM IODIDE; FLUORODEOXYGLUCOSE F 18; IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COLLIMATED SCINTILLATOR; COLLIMATOR; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; RADIATION DETECTION; SCINTIGRAPHY; SCINTILLATION PROBE; SIGNAL NOISE RATIO; THYROID CANCER;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HUMANS; INTRAOPERATIVE CARE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURGERY, COMPUTER-ASSISTED; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 34748850080     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0393-6     Document Type: Article

References (20)

1. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of sentinel node in breast cancer using a gamma probe. Surg Oncol 1993;2:335-40.
2. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-7.
3. 131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 1998;83:2675-80.
4. Peltier P, Curtet C, Chatal JF, Le Doussal JM, Daniel G, Aillet G, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993;34:1267-73.
5. 111In-pentetreotide: a pilot study. Tumori 2005;91:173-6.
6. 18F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res 2001;96:120-6.
7. 18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study. J Surg Res 2001;97:9-13.
8. 131I scanning results after therapy. J Nucl Med 2001;42:1464-9.
9. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-92.
10. Uematsu H, Sadato N, Ohtsubo T, Tsuchida T, Nakamura S, Sugimoto K, et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 1998;39:453-9.
11. 18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001;234:804-11.
12. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
13. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:3779-86.
14. Gulec SA, Lee J, Morton DL. GLUT-1 expression correlates with overall and post-resection survival in patients with metastatic pulmonary melanoma. Eur J Nucl Med 2005;32 Suppl 1:S113.
15. 18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328-34.
16. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5.
17. National Electrical Manufacturers Association. NEMA Standards Publication NU 3-2004. Performance measurements and quality control guidelines for non-imaging intraoperative gamma probes. Rosslyn, VA: National Electrical Manufacturers Association, 2004.
18. Zanzonico P, Heller S. The intraoperative gamma probe: basic principles and choices available. Semin Nucl Med 2000;30:33-4.
19. Daghighian F, Mazziotta JC, Hoffman EJ, Shenderov P, Eshaghian B, Siegel S, et al. Intraoperative beta probe: a device for detecting tissue labeled with positron or electron emitting isotopes during surger. Med Phys 1994;21:153-7.
20. Hickernell TS, Barber HB, Barrett HH, Woolfenden JM. Dual-detector probe for surgical tumor staging. J Nucl Med 1988;29:1101-6.